Population Study: Cancer Survival Rates Improved After FDA-Approval of Bevacizumab

A population-based study from the Mayo Clinic has found that individuals who succumbed to glioblastoma in 2010 lived significantly longer than those who died from the disease in 2008, prior to the Food and Drug Administration’s (FDA’s) approval of bevacizumab as a cancer treatment. “There has been a great deal of debate about the effectiveness of bevacizumab in treating patients with glioblastoma,” says the study’s lead author Derek Johnson, MD, a neuro-oncologist at Mayo Clinic Cancer Center. “Our study found that, at the population level, treatment strategies involving bevacizumab prolonged survival in patients with progressive glioblastoma.” Click here to read the full story.